Merck Enters The Alzheimer’s Disease Race, Plans Filings For Five New Drugs

As Merck heads into a “patent cliff” year, highlights of its analyst meeting included updates on key Phase III drugs, growth in emerging markets, and unveiling of new programs in Alzheimer’s disease and diabetes.